 Sanofis SNY Nexviadyme is approved for the treatment of both late-onset Pompe disease and infantile-onset Pompe disease. Xenpozyme is approved for non-Central Nervous System CNS manifestations of acid sphingomyelinase deficiency ASMD disease. 